Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.1 Million Ordinary Shares
SEC Form 4 Filing
Priti Hegde, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 1,144,686 ordinary shares on July 1, 2024.
Summary
- On July 1, 2024, Priti Hegde, a director of Adaptimmune Therapeutics PLC, filed a Form 4 indicating a change in beneficial ownership.
- Hegde acquired options to purchase 1,144,686 ordinary shares of Adaptimmune Therapeutics PLC.
- The exercise price of the options is $0.16 per share, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
- The options are exercisable from July 1, 2025, and expire on July 1, 2034.
- The options were acquired directly by Hegde.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Positives
- A director's acquisition of options may signal confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders, as it reflects a director's investment decision.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Director acquired options to purchase ordinary shares. |
| 07/01/2025 | Options become exercisable. |
| 07/01/2034 | Options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.